Patents Represented by Attorney, Agent or Law Firm Bruce A. Pokras
-
Patent number: 5747066Abstract: Mixed micelles for the aqueous solubilization of active substances which are difficultly soluble or insoluble in water with improved storage properties consist of a phosphatide having saturated, branched fatty acid residues and a bile acid salt or dihexanoyllecithin.Type: GrantFiled: March 7, 1996Date of Patent: May 5, 1998Assignee: Hoffmann-La Roche Inc.Inventors: Folker Pittrof, Hans Steffen
-
Patent number: 5702579Abstract: A process for the preparation of ascorbic acid starting from an ascorbate is characterized in that an ascorbate, e.g. sodium ascorbate, dissolved in water is decomposed under the influence of an electric field by means of ion-selective membranes into ascorbate ions and cations and the latter are separated spatially from one another and then, as a result of simultaneous generation of protons and hydroxide ions, the ascorbic acid is prepared from the liberated ascorbate ions and protons and, spatially separated therefrom, the corresponding hydroxide, e.g. sodium hydroxide, is also prepared from the cations and hydroxide ions.Type: GrantFiled: December 13, 1996Date of Patent: December 30, 1997Assignee: Roche Vitamins Inc.Inventor: Joachim Veits
-
Patent number: 5700836Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is a residue of the formula ##STR2## and R.sup.2 -R.sup.10 have the significance given in the specification can be used as pharmaceuticals, particularly for the repair of photodamaged skin, other dermatological conditions, and oncological indications.Type: GrantFiled: October 21, 1996Date of Patent: December 23, 1997Assignee: Hoffmann-La Roche Inc.Inventors: Michael Klaus, Peter Mohr
-
Patent number: 5693755Abstract: A synthetic gene which codes for at least one epitope from the immunodominant conserved region of HTLV-I env. gp 21 as well as hybrid genes utilizing the synthetic gene in conjunction with other epitopes from HTLV-Ienv.Type: GrantFiled: October 21, 1994Date of Patent: December 2, 1997Assignee: Hoffmann-La Roche Inc.Inventors: Deborah Anne Buonagurio, Mathew Longiaru
-
Patent number: 5688946Abstract: The compounds of the formula ##STR1## in the form of optically pure diastereomers, mixtures of diastereomers, diastereomeric racemates or mixtures of diastereomeric racemates as well as pharmaceutically usable salts thereof inhibit the activity of the natural enzyme renin and can accordingly be used in the form of pharmaceutical preparations in the control or prevention of high blood pressure and cardiac insufficiency.Type: GrantFiled: July 19, 1994Date of Patent: November 18, 1997Assignee: Hoffmann La Roche Inc.Inventors: Quirico Branca, Werner Neidhart, Henri Ramuz, Heinz Stadler, Wolfgang Wostl
-
Patent number: 5681977Abstract: Novel processes and intermediates useful for the manufacture of the Wittig ester salts are disclosed. The Wittig ester salts are known as important C.sub.5 building blocks for the manufacture of various polyenecarboxylic acid esters in the field of carotenoid chemistry.Type: GrantFiled: January 7, 1997Date of Patent: October 28, 1997Assignee: Roche Vitamins Inc.Inventors: Bruno Burdet, August Ruttimann, Jean-Marie Santer, Theodor Siegfried
-
Patent number: 5677419Abstract: Analogs of porcine Vasoactive Intestinal Peptide are disclosed. The analogs have been cyclized by the covalent attachment, via an amide bond, of the side-chain carboxy terminus of one amino acid in the peptide chain to the side-chain amino terminus of another amino acid in the peptide chain. The claimed compounds are useful for the treatment of asthma.Type: GrantFiled: September 19, 1994Date of Patent: October 14, 1997Assignee: Hoffmann-La Roche Inc.Inventors: David Robert Bolin, Margaret O'Donnell
-
Patent number: 5672513Abstract: The present invention provides recombinant CEA glycoproteins and methods for their production. These recombinant CEA glycoproteins s lack the C-terminal 26 amino acids which are present in natural CEA and are characterized in that they are free from cross-reactive CEA-like antigens, antigenically indistingiushable from the soluble form of CEA shed from tumor cells, and devoid of the ethanolamine which is present at the C-terminus of natural CEA, and also devoid of the additional amino acids which may be attached to the natural CEA through said ethanolamine. Said recombinant CEA glycoproteins s preferably have the amino acid sequence SEQ ID NO: 1. The CEA glycoproteins s of the invention may be used as reagents in an immunoassay for the diagnosis of neoplastic diseases. The invention also relates to a DNA encoding said recombinant CEA glycoprotein, such as the DNA having the nucleotide sequence SEQ ID NO: 2 or a functional equivalent sequence thereof.Type: GrantFiled: March 23, 1994Date of Patent: September 30, 1997Assignee: Roche Diagnostic Systems, Inc.Inventors: Alexey Terskikh, Andre Pelegrin, Jean-Pierre Mach
-
Patent number: 5670548Abstract: A method of pigmenting certain parts and products of poultry, fish and crustacea by including in the feed of the pertinent animal one or more of the carotenoids 2'-dehydroplectaniaxanthin, desmethylspheroidenone, spheroidenone, 1-hydroxy-3,4-didehydro-1,2-dihydro-.psi.,.psi.-caroten-2-one, 5'-hydroxy-5',6'-dihydro-4'-apo-.beta.-caroten-6'-one, 1'-hydroxy-3',4'-didehydro-1',2'-dihydro-.beta.,.psi.-carotene-4,2'-dione and 5'-hydroxy-5',6'-dihydro-4'-apo-.beta.-carotene-4,6'-dione, poultry, fish and crustacea feeds for pigmenting certains parts and products of these animals, beadlets and premixes for adding to poultry, fish and crustacea feeds, and the carotenoids 1-hydroxy-3,4-didehydro-1,2-dihydro-.psi.,.psi.-caroten-2-one, 5'-hydroxy-5',6'-dihydro-4'-apo-.beta.-caroten-6'-one, 1'-hydroxy-3',4'-didehydro-1',2'-dihydro-.beta.,.psi.-carotene-4,2'-dione and 5'-hydroxy-5',6'-dihydro-4'-apo-.beta.-carotene-4,6'-dione.Type: GrantFiled: October 7, 1996Date of Patent: September 23, 1997Assignee: Roche Vitamins Inc.Inventors: Kurt Bernhard, Jiri Broz, Urs Hengartner, Paul Kreienbuhl, Katharina Schiedt
-
Patent number: 5665581Abstract: This invention is directed to naturally virulent fungi which have cells transfected with the coding strand of a mycovirus RNA and which have reduced ability to cause disease in plants, and to compositions and methods of treatment of fungal disease with these fungi.Type: GrantFiled: June 3, 1994Date of Patent: September 9, 1997Assignee: Hoffmann-La Roche Inc.Inventors: Baoshan Chen, Gil Ho Choi, Donald Lee Nuss
-
Patent number: 5648482Abstract: A method for the detection of poor metabolizers of drugs using PCR technology is described comprising a) optionally amplifying a gene coding for an enzyme known to be responsible for the metabolization of drugs, thereby separating it from possible closely related pseudogens,b) amplifying different allelic forms of the gene of step a) and c) detecting the product of step b). Primers for amplification of the genes responsible for the debrisoquine or acetylation phenotype are also disclosed.Type: GrantFiled: March 2, 1994Date of Patent: July 15, 1997Assignee: Hoffmann-La Roche Inc.Inventor: Urs Albert Meyer
-
Patent number: 5644024Abstract: The present invention is concerned with tetrahydronaphthalene derivatives which are mimics of domains of peptides or proteins which can interact with other proteins or with DNA or RNA through .alpha.-helical conformation, said tetrahydronaphthalene derivatives having the formulae: ##STR1## are valuable aids in the determination of biologically active peptide sequences and are accordingly so-called "research tools". They are, however, also potentially suitable as medicaments.Type: GrantFiled: August 17, 1994Date of Patent: July 1, 1997Assignee: Hoffmann-La Roche Inc.Inventors: Christine Abrecht, Klaus Muller, Daniel Obrecht, Arnold Trzeciak
-
Patent number: 5639660Abstract: A Polypeptide and DNA Sequence corresponding to the human receptor high affinity receptor for IgE as well as replicable microbial expression vehicles, transformed microorganisms, and cultures of microbial cells which produce this polypeptide.Type: GrantFiled: February 24, 1988Date of Patent: June 17, 1997Assignees: Hoffmann-La Roche Inc., The United States of America as represented by the Department of Health and Human ServicesInventors: Jean Pierre Kinet, Jarema Peter Kochan
-
Patent number: 5631398Abstract: A processes and intermediates useful for the manufacture of the Wittig ester salts are disclosed. The Wittig ester salts are known as important C.sub.5 building blocks for the manufacture of various polyenecarboxylic acid esters in the field of carotenoid chemistry.Type: GrantFiled: November 16, 1995Date of Patent: May 20, 1997Assignee: Roche Vitamins Inc.Inventors: Bruno Burdet, August R uttimann, Jean-Marie Santer, Theodor Siegfried
-
Patent number: 5600015Abstract: There is described a process for the manufacture of isoprene derivatives of the general formula ##STR1## wherein the asymmetric centres can each individually have the (R)- or (S)-configuration, R represents a residue of the formulae ##STR2## R.sup.1 signifies lower alkyl or both R.sup.1 's together signify ethylene or propylene and n stands for the number 0, 1 or 2,in which a compound, which is present in the (E)- or (Z)-form, of the general formula ##STR3## wherein R, n and an optionally present asymmetric centre have the above significance,is asymmetrically hydrogenated with a ruthenium complex of an optically active atropisomeric diphosphine.Type: GrantFiled: May 19, 1995Date of Patent: February 4, 1997Assignee: Hoffmann-La Roche Inc.Inventors: Emil A. Broger, Robert K. M uller
-
Patent number: 5595999Abstract: Compounds of the formula ##STR1## wherein L, M, R, T and X are set forth in the description, as well as hydrates or solvates thereof, which inhibit thrombin-induced platelet aggregation and clotting of fibrinogen in plasma, are described. The compounds of formula I are prepared by amidination or, depending on whether L is NH or O, by amide formation or esterification.Type: GrantFiled: June 7, 1995Date of Patent: January 21, 1997Assignee: Hoffmann-La Roche Inc.Inventors: Jean Ackermann, David Banner, Klaus Gubernator, Paul Hadvary, Kurt Hilpert, Klaus M uller, Ludvik Labler, G erard Schmid, Thomas B. Tschopp, Hans P. Wessel, Beat Wirz
-
Patent number: 5583133Abstract: Compounds of the formula ##STR1## wherein L, M, R, T and X are set forth in the description, as well as hydrates or solvates thereof, which inhibit thrombin-induced platelet aggregation and clotting of fibrinogen in plasma, are described. The compounds of formula I are prepared by amidination or, depending on whether L is NH or O, by amide formation or esterification.Type: GrantFiled: August 4, 1995Date of Patent: December 10, 1996Assignee: Hoffmann-La Roche Inc.Inventors: Jean Ackermann, David Banner, Klaus Gubernator, Paul Hadvary, Kurt Hilpert, Klaus M uller, Ludvik Labler, G erard Schmid, Thomas B. Tschopp, Hans P. Wessel, Beat Wirz
-
Patent number: 5583248Abstract: Compounds of the formula: ##STR1## wherein R.sup.1 is alkoxycarbonyl, aralkoxycarbonyl, alkanoyl, aralkanoyl, heterocyclylcarbonyl or a group of the formula: ##STR2## R.sup.2 is alkyl, cycloalkylalkyl or aralkyl; R.sup.3 is hydrogen and R.sup.4 is hydroxy or R.sup.3 and R.sup.4 together are oxo; R.sup.5 is alkoxycarbonyl or alkylcarbamoyl; R.sup.6 and R.sup.7 together are trimethylene or tetramethylene optionally substituted by alkyl or on adjacent carbon atoms by tetramethylene; R.sup.8 is alkoxycarbonyl, aralkoxycarbonyl, alkanoyl, aroyl, aralkanoyl or heteroeyelylearbonyl; and R.sup.9 is alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, cyanoalkyl, carbamoyl-alkyl, alkylthioalkyl, alkoxyalkyl or alkoxycarbonylalkyl:and pharmaceutically acceptable acid addition salts of those compounds of formula I which are basic, inhibit aspartyl proteases of viral origin and can be used in the form of medicaments for the prophylaxis or treatment of viral infections.Type: GrantFiled: April 5, 1995Date of Patent: December 10, 1996Assignee: Hoffmann-La Roche Inc.Inventors: Joseph A. Martin, Gareth J. Thomas
-
Patent number: 5583222Abstract: The compounds of formula I ##STR1## wherein R.sup.1 -R.sup.9, R.sup.15, A, X, Y, Z and n have the meaning given in the specification are active as protein kinase inhibitors and can be used as medicaments, particularly for the treatment of inflammatory skin disorders and alopecia.Type: GrantFiled: January 4, 1995Date of Patent: December 10, 1996Assignee: Hoffmann-La Roche Inc.Inventors: Pierre Barbier, Isabelle Huber, Fernand Schneider, Josef Stadlwieser, Sven Taylor
-
Patent number: 5578730Abstract: A process for the production of a .beta.-aminoalcohol 2-[3(S)-amino-2-hydroxy-4-phenylbutyl]-N-tert.butyl-decahydro-(4aS,8aS)-is oquinoline-3(S)-carboxamide of the formula ##STR1## via the oxazolidinone corresponding to the aminoalcohol 10 which process comprises refluxing a sulphonic acid ester with a carboxamide in the presence of a base and a solvent.Type: GrantFiled: March 9, 1995Date of Patent: November 26, 1996Assignee: Hoffmann-La Roche Inc.Inventor: Hans Hilpert